Daiichi Sankyo launches Sevikar HCT in UK

Daiichi Sankyo has announced the UK launch of Sevikar HCT, its innovative combination therapy for hypertension.

The three-in-one therapy option combines olmesartan medoxomil, amlodipine and hydrochlorothiazide into a single tablet, making it more convenient for those having trouble taking multiple pills.

According to the company, providing a single-pill fixed-dose treatment option will help to improve compliance with prescribed regimens, as well as offering better blood pressure control than separately administered compounds.

Sevikar HCT is being made available in five different dosage options to allow clinicians to select the right strength for individual patients.

Professor Tony Heagerty, head of the cardiovascular research group at Manchester University, said: "It is important to address adherence issues when they crop up and support our patients where we can to help insure their futures against stroke."

Earlier this month, the pharmaceutical company agreed a new licensing deal with ArQule, pertaining to the promising developmental cancer compound ARQ 092.